Reaction Details | |||
---|---|---|---|
Report a problem with these data | |||
Target | ALK tyrosine kinase receptor | ||
Ligand | BDBM50396259 | ||
Substrate/Competitor | n/a | ||
Meas. Tech. | ChEMBL_863887 (CHEMBL2176371) | ||
IC50 | 2±n/a nM | ||
Citation | Lewis, RT; Bode, CM; Choquette, DM; Potashman, M; Romero, K; Stellwagen, JC; Teffera, Y; Moore, E; Whittington, DA; Chen, H; Epstein, LF; Emkey, R; Andrews, PS; Yu, VL; Saffran, DC; Xu, M; Drew, A; Merkel, P; Szilvassy, S; Brake, RL The discovery and optimization of a novel class of potent, selective, and orally bioavailable anaplastic lymphoma kinase (ALK) inhibitors with potential utility for the treatment of cancer. J Med Chem55:6523-40 (2012) [PubMed] Article | ||
More Info.: | Get all data from this article, Assay Method | ||
ALK tyrosine kinase receptor | |||
Name: | ALK tyrosine kinase receptor | ||
Synonyms: | ALK | ALK tyrosine kinase receptor (ALK) | ALK_HUMAN | Anaplastic lymphoma kinase | CD_antigen: CD246 | ||
Type: | Protein | ||
Mol. Mass.: | 176453.10 | ||
Organism: | Homo sapiens (Human) | ||
Description: | Q9UM73 | ||
Residue: | 1620 | ||
Sequence: |
| ||
BDBM50396259 | |||
n/a | |||
Name | BDBM50396259 | ||
Synonyms: | CHEMBL2172325 | ||
Type | Small organic molecule | ||
Emp. Form. | C29H37N5O2 | ||
Mol. Mass. | 487.6364 | ||
SMILES | CCNC(=O)[C@H]1CC[C@H](CC1)n1c(NC(=O)c2ccccc2)nc2ccc(CN3CCCCC3)cc12 |r,wU:8.11,5.4,(15.62,-34.99,;14.12,-34.68,;13.64,-33.21,;12.13,-32.89,;11.1,-34.04,;11.65,-31.43,;10.15,-31.11,;9.67,-29.66,;10.7,-28.51,;12.2,-28.81,;12.68,-30.28,;10.21,-27.05,;11.12,-25.79,;12.66,-25.78,;13.42,-24.44,;12.64,-23.11,;14.96,-24.43,;15.73,-25.76,;17.27,-25.75,;18.04,-24.41,;17.25,-23.08,;15.71,-23.09,;10.2,-24.54,;8.73,-25.03,;7.39,-24.26,;6.06,-25.03,;6.06,-26.58,;4.73,-27.35,;3.39,-26.58,;3.39,-25.04,;2.07,-24.27,;.73,-25.03,;.73,-26.57,;2.06,-27.35,;7.4,-27.35,;8.74,-26.58,)| | ||
Structure |